Nadine McCleary, MD, MPH

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Nadine McCleary, MD, MPH sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

Nadine McCleary, MD, MPH: 1 sponsored US clinical trial, 1 recruiting.

Nadine McCleary, MD, MPH sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Thoracic Cancer, with 1 trials.

Mid-pack sponsor footprint

Nadine McCleary, MD, MPH is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING NA

SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)

NCT05375643

Therapeutic Areas

Thoracic Cancer 1
Hematologic Cancer 1
Gastrointestinal Cancer 1

What is open in the Nadine McCleary, MD, MPH pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Thoracic Cancer (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Nadine McCleary, MD, MPH: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Nadine McCleary, MD, MPH sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Nadine McCleary, MD, MPH1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Nadine McCleary, MD, MPH sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Nadine McCleary, MD, MPH sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Nadine McCleary, MD, MPH page

1 registered trials is a research-attention snapshot, not an endorsement of Nadine McCleary, MD, MPH or any single study.

  • 1 of Nadine McCleary, MD, MPH's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Thoracic Cancer is the condition Nadine McCleary, MD, MPH studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Thoracic Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Nadine McCleary, MD, MPH pipeline card: 1 registered trials from official public datasets.Report a data error.